Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Zepbound is a subcutaneous injection that needs proper storage and handling during travel. There are ways you can travel with Zepbound to ensure it remains safe and effective to use. Zepbound ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Zepbound is both a GLP-1 receptor agonist and a GIP receptor agonist, so it helps reduce appetite and food intake. It is a subcutaneous injection that a person administers once a week. The ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy ... find a more powerful competitor to Lilly's Zepbound, also known as Mounjaro.

GLP-1RA drugs, including Mounjaro and Zepbound, are administered weekly via injection and work by simulating hormones that curb appetite and slow digestion, promoting longer-lasting satiety.

Mounjaro and Zepbound are part of a wave of diabetes ... globally due to the amount of weight people lose while taking the injections. They compete with Ozempic and Wegovy from the Danish ...